The population was enriched with a sicker phenotype than prior trials, which may have enhanced the impact on hard outcomes.
The trial is “a turning point” in the management of moderate AS, says Philippe Généreux, adding that the disease is not benign.
The rates of TLF were considerably lower than the investigators expected, leading to questions about experience and selection ...
REMEDY-PILOT showed the safety and feasibility of using the device, but with no effects on perfusion or angina symptoms.
SAN DIEGO, CA—Patients treated with the Agent drug-coated balloon (DCB; Boston Scientific) have encouraging outcomes at 1 ...
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...
The decrease in death/HF with a single subcutaneous injection of the novel GP IIb/IIIa inhibitor seen at 30 days persisted.
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results